- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Patent holdings for IPC class A61K 31/517
Total number of patents in this class: 5974
10-year publication summary
411
|
420
|
387
|
399
|
415
|
481
|
491
|
537
|
413
|
167
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Genentech, Inc. | 3742 |
94 |
Boehringer Ingelheim International GmbH | 4629 |
91 |
Novartis AG | 11238 |
85 |
AstraZeneca AB | 3042 |
85 |
F. Hoffmann-La Roche AG | 7958 |
61 |
The Regents of the University of California | 18943 |
61 |
Array BioPharma Inc. | 551 |
54 |
Merck Patent GmbH | 5909 |
51 |
Bristol-myers Squibb Company | 5080 |
49 |
AstraZeneca UK Limited | 768 |
46 |
Janssen Pharmaceutica N.V. | 3839 |
46 |
Celgene Corporation | 1412 |
42 |
Gilead Sciences, Inc. | 1879 |
42 |
Resverlogix Corp. | 64 |
39 |
Sunshine Lake Pharma Co., Ltd. | 542 |
39 |
Amgen Inc. | 3779 |
38 |
Dana-Farber Cancer Institute, Inc. | 2455 |
37 |
Merck Sharp & Dohme LLC | 3689 |
37 |
Board of Regents, The University of Texas System | 5370 |
32 |
The Trustees of the University of Pennsylvania | 4122 |
32 |
Other owners | 4913 |